Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 7/20 | 0.42 |
| ▸ | AR | P10275 | 5/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.36 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | GSK3A | P49840 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5356806 | 1.00 | IDH1 (0.42) | IDH1ARCCR1CCR2GRM2 | |
| SCHEMBL14561817 | 0.82 | P2RX3 (0.44) | IDH1CCR1CCR2GRM2P2RX3 | |
| SCHEMBL5513575 | 0.78 | AR (0.40) | ARCCR1CCR2GRM2GSK3A | |
| SCHEMBL5509172 | 0.78 | AR (0.40) | ARCCR1CCR2GRM2GSK3A | |
| SCHEMBL5509169 | 0.78 | AR (0.40) | ARCCR1CCR2GRM2GSK3A | |
| SCHEMBL2366511 | 0.77 | P2RX3 (0.42) | P2RX3P2RX2 | |
| SCHEMBL2366506 | 0.77 | P2RX3 (0.42) | P2RX3P2RX2 | |
| SCHEMBL9892985 | 0.75 | PTGER2 (0.48) | CCR1CCR2GRM2GSK3AGSK3B | |
| SCHEMBL5370694 | 0.72 | KDM1A (0.35) | ARGRM2HSD11B1GSK3AGSK3B | |
| SCHEMBL5359605 | 0.72 | KDM1A (0.35) | ARGRM2HSD11B1GSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070049759-A1 | Methods for Preparing N-Arylated Oxazolidinones Via A Copper Catalyzed Cross Coupling | PFIZER INC | 2007-03-01 | — | — | US | claimed |
| EP-1562916-A1 | METHODS FOR PREPARING N-ARYLATED OXAZOLIDINONES VIA A COPPER CATALYZED CROSS COUPLING REACTION | Pfizer Products Inc. (US) | 2005-08-17 | — | — | EP | claimed |
| US-20040122226-A1 | Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction | PFIZER INC | 2004-06-24 | — | — | US | claimed |
| WO-2004039788-A1 | METHODS FOR PREPARING N-ARYLATED OXAZOLIDINONES VIA A COPPER CATALYZED CROSS COUPLING REACTION | PFIZER PRODUCTS INC. (US) | 2004-05-13 | — | — | WO | claimed |
| US-7223870-B2 | Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction | PFIZER INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223870-B2 | Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction | PFIZER INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223870-B2 | Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction | PFIZER INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20070049759-A1 | Methods for Preparing N-Arylated Oxazolidinones Via A Copper Catalyzed Cross Coupling | PFIZER INC | 2007-03-01 | — | — | US | disclosed |
| US-20070049759-A1 | Methods for Preparing N-Arylated Oxazolidinones Via A Copper Catalyzed Cross Coupling | PFIZER INC | 2007-03-01 | — | — | US | disclosed |
| US-20070049759-A1 | Methods for Preparing N-Arylated Oxazolidinones Via A Copper Catalyzed Cross Coupling | PFIZER INC | 2007-03-01 | — | — | US | disclosed |
| EP-1562916-A1 | METHODS FOR PREPARING N-ARYLATED OXAZOLIDINONES VIA A COPPER CATALYZED CROSS COUPLING REACTION | Pfizer Products Inc. (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20040122226-A1 | Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction | PFIZER INC | 2004-06-24 | — | — | US | disclosed |
| WO-2004039788-A1 | METHODS FOR PREPARING N-ARYLATED OXAZOLIDINONES VIA A COPPER CATALYZED CROSS COUPLING REACTION | PFIZER PRODUCTS INC. (US) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049759-A1 | Methods for Preparing N-Arylated Oxazolidinones Via A Copper Catalyzed Cross Coupling | AOC2, SOD1, AOC3 | IDH1 86/4885AR 2607/4885CCR1 3225/4885 |
| US-20040122226-A1 | Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction | AOC2, SOD1, AOC3 | IDH1 120/4885AR 2506/4885CCR1 3216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.